Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 11/20 | 0.35 |
| ▸ | CDK8 | P49336 | 11/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850571 | 0.84 | CCNC (0.47) | CCNCCDK8KDM4EKMT2AALDH1A1 | |
| SCHEMBL578828 | 0.84 | CCNC (0.47) | CCNCCDK8KDM4EKMT2AALDH1A1 | |
| SCHEMBL12114716 | 0.83 | CCNC (0.37) | CCNCCDK8KDM4EKMT2AALDH1A1 | |
| SCHEMBL10138247 | 0.83 | CCNC (0.40) | CCNCCDK8ALDH1A1 | |
| SCHEMBL1319809 | 0.83 | CCNC (0.49) | CCNCCDK8KMT2APIM1 | |
| Hydrochloric Acid SCHEMBL4580182 | 0.83 | CCNC (0.46) | CCNCCDK8KDM4EKMT2AALDH1A1 | |
| SCHEMBL4580779 | 0.79 | MAPK1 (0.42) | CCNCCDK8KDM4EALDH1A1 | |
| SCHEMBL4579695 | 0.79 | CCNC (0.52) | CCNCCDK8 | |
| SCHEMBL4728279 | 0.79 | ALDH1A1 (0.47) | CCNCCDK8KDM4EALDH1A1 | |
| SCHEMBL17437118 | 0.75 | CCNC (0.56) | CCNCCDK8ALDH1A1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | disclosed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885KDM4E 3744/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | CCNC 289/4885CDK8 516/4885KDM4E 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.